版本:
中国

BRIEF-Oncomed Pharma says to initiate Phase 1a single-agent study of OMP-313M32 in first half of 2017

April 3 Oncomed Pharmaceuticals Inc:

* Plans to initiate a phase 1a single-agent study of its anti-TIGIT antibody (OMP-313M32) in first half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐